Nuveen’s MapLight Therapeutics MPLT Stock Holding History

Nuveen’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$469K	Buy	23,089 +2,892	+14%	+$51.7K	﹤0.01%	2862
2025 Q4	$355K	Buy	+20,197	New	+$338K	﹤0.01%	2997

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's MPLT Position: Q1 2026 in Review

Nuveen increased its MapLight Therapeutics (MPLT) stake by 14% in Q1 2026, buying an estimated $51.7K and bringing the position to 23,089 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #2862.

Nuveen first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

Nuveen held 23,089 shares of MapLight Therapeutics worth $469K as of Q1 2026.
Nuveen bought 2,892 MapLight Therapeutics shares in Q1 2026, an estimated $51.7K.
MapLight Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2862 holding.
Nuveen first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.